Biological Mimetics

Biological Mimetics is a private, pre-revenue biotechnology company with a 25+ year history, specializing in novel vaccine and diagnostic platforms. Its lead technologies include IRT (Immune Refocusing Technology) for creating more broadly protective vaccines and MDP (Manganese-Decapeptide-Phosphate) for pathogen inactivation, with an advanced program in ultraIPV (inactivated polio vaccine). The company also collaborates on FAST, a portable CRISPR-based diagnostic tool designed for low-resource settings. BMI operates through partnerships to advance its platforms toward the market.

IRT (Immune Refocusing Technology): Bioinformatic platform to identify and dampen immune response to variable decoy epitopes, refocusing immunity to conserved sites. MDP (Manganese-Decapeptide-Phosphate): Pathogen inactivation system adapted from radiation-resistant bacteria for vaccine development. FAST: Instrument-free, multi-chambered diagnostic platform integrating RPA amplification and CRISPR cleavage for nucleic acid detection.

In universal vaccines, BMI competes with large pharma (e.g., Sanofi, GSK) and biotechs (e.g., Moderna, CureVac) pursuing similar goals. In polio vaccines, it faces established players like Sanofi. Its FAST diagnostic enters a crowded point-of-care market with competitors like Mammoth Biosciences and Sherlock Biosciences, though its instrument-free design targets a specific niche.